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Abstract 
 
Alzheimer’s disease (AD) and vascular dementia (VaD) are the two most common causes of 
dementia in old people. They remain difficult to differentiate in practice because of lack of 
sensitivity and specificity of current clinical diagnostic criteria. Recent molecular and cellular 
advancements indicate that the use of cerebrospinal fluid markers may improve early 
detection and differential diagnosis of AD. Our objective in this study was to determine 
diagnostic accuracy of three cerebrospinal (CSF) markers: total tau protein (t-tau), tau protein 
phosphorylated on threonine 181 (p-tau181) and tau protein phosphorylated on serine 199 (p-
tau199). Using commercially available ELISA kits concentrations of t-tau, p-tau181 and p-
tau199 were analyzed in 12 patients with probable AD, 9 patients with VaD and 12 NC 
subjects. The median levels of all three markers were significantly higher in AD group versus 
VaD and NC groups. However, when the sensitivity levels were set to 85% or higher, only t-
tau and p-tau199 satisfied consensus recommendations (specificity more than 75%) when 
differentiating AD from VaD. In conclusion, our preliminary data on a small group of 
selected subjects suggest that the CSF t-tau and p-tau199 levels are useful markers for 
differentiating AD from VaD. 
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Introduction 
 
Development of novel therapeutic options as well as unsatisfactory sensitivity and specificity 
of current clinical diagnostic criteria for Alzheimer’s disease (AD) require additional markers 
to help in early and accurate differentiation of AD from other dementias1. Besides amyloid 
plaques (AP), another important pathological hallmark of AD includes neurofibrillary tangles 
(NFT) which are mainly composed of hyperphosphorylated tau. Formation of both AP and 
NFT begins at least 20–30 years before the clinical onset of the disease2. During the years, 
progressive accumulation of the neuropathological changes eventually leads to appearance of 
first symptoms. Interestingly, the development of NFT, but not of AP, typically follows 
pattern of progression in topographical terms3,4. In contrast to AD, vascular dementia (VaD) 
is not characterized with formation of NFT. Due to the fact that biochemical changes in the 
brain are reflected in the CSF, in this context tau proteins may represent a promising 
biological marker for differentiating AD from VaD. AD and VaD are the two most common 
dementia types in old people. Although they are clearly separate diseases, to differentiate 
them is often a serious problem in clinical practice, especially because of »mixed dementia « 
cases where characteristics of AD and VaD may persist concurrently. The best clinical 
discriminative factors for VaD versus AD include step-by-step progression, prominent 
impairment of executive functions, Hachinski ischemic score >4, and focal neurological signs 
implying extensive cortical and subcortical lesions5,6. In this study we analyzed CSF levels 
of total tau protein (t-tau), tau protein phosphorylated on threonine 181 (p-tau181) and tau 
protein phosphorylated on serine 199 (p-tau199) in patients with AD and VaD, as well as in 
control, cognitively normal subjects (NC). We wanted to test the diagnostic accuracy of these 
markers in the CSF in differentiation of AD from VaD and NC. 
Materials and Methods 
 
Subjects 
 
A total of 21 patients were included in this pilot study. All patients fulfilled DSM-IV criteria 
for dementia7. Among the patients who fulfilled NINCDS-ADRDA criteria for probable 
AD1, those with significant white matter changes on neuroimaging and/or Hachinski ischemic 
score >4 were excluded from the study. Finally, twelve patients with probable AD were 
recruited. Nine patients fulfilled NINCDS-AIREN criteria for VaD8. To exclude secondary 
causes of dementia, during the initial work-up all patients underwent general and neurological 
examination, Mini Mental State Examination (MMSE), complete blood tests including 
electrolytes, thyroid function, albumin, levels of vitamin B12, VDRL, ECG and neuroimaging 
(CT or MRI scan of the brain). Patients without secondary causes of dementia finally 
underwent lumbar puncture for CSF analysis. None of the patients was under therapy 
with cholinesterase inhibitors or memantine. Additionally, 12 control subjects (NC) with no 
evidence of the cognitive decline, who were otherwise phy- sically and mentally healthy, were 
included in the study. More detailed data on subjects analyzed are given in Table 1. Study 
participants were recruited from the Department of Neurology, Ludwig-Maximilian 
University, Munich, Germany, and Department of Neurology, University Hospital 
Centre, Zagreb, Croatia. The study was approved by both local ethical committees and the 
Central ethical committee of the Zagreb Medical School. All patients consented that their CSF 
can be used for scientific studies. 
 
CSF sampling and analysis 
 
Lumbar puncture was performed after informed consent had been obtained. CSF was taken by 
a routine protocol in the L3/L4 or L4/L5 intervertebral space and was always performed 
between 9 a.m. and 11 a.m. CSF samples were collected in propylene tubes. Determination of 
routine biochemical parameters (leukocyte and erythrocyte cell count, glucose, lactate, total 
protein concentration, IgG index, TPHA) was performed using native CSF. The rest of the 
CSF sample was centrifuged for 10 minutes at 10,000 g, and aliquots of the remaining 
supernatant were immediately frozen at –80 oC for later t-tau, p-tau181, and p-tau199 protein 
determination. CSF analysis was performed in the Laboratory for Developmental 
Neuropathology of the Croatian Institute for Brain Research, Zagreb, by using enzyme-linked 
immunosorbent assay (ELISA). CSF t-tau and p-tau199 levels were determined by using 
Biosource International (Camarillo, CA, USA) ELISA kits, whereas the levels of t-tau were 
determined by using the ELISA kit Innotest hTau-Ag (Innogenetics NV, Ghent, Belgium). All 
three tests were carried-out according to the manufacturers’ protocols. 
 
Statistical analysis 
 
Obtained data on CSF t-tau, p-tau181, and p-tau199 were presented as medians with 25th and 
75th percentiles because the values were not normally distributed. Levels of total tau and 
phospho-tau markers were compared between groups using nonparametric Kruskal-Wallis 
ANOVA (as a test for the overall group differences), followed by the Mann-Whitney U test 
for pairwise comparisons. Cut-off levels of all of the markers used in the study were derived 
from the receiver operating characteristic (ROC) curve analysis, when the sum of sensitivity 
and specificity was maximized. Sensitivity and specificity were given with respective 95% 
CI. Additionally, areas under the curve (AUC) were calculated. The effect of MMSE score 
were tested separately in each diagnostic group by the Spearman’s rank correlation coefficient 
(Rs). Statistical analysis was performed using SPSS v.12.0.1. P values less than 0.05 were 
considered statistically significant. 
Results 
 
Study cohort 
 
Demographic data of the subjects included in the study are presented in Table 1. When 
comparing mean age of participants no significant differences were found between groups. 
The relationships between MMSE scores and t-tau, p-tau181 and p-tau199 were analyzed. 
None of the parameters showed a significant correlation with MMSE score as shown in Table 
2. 
 
CSF biomarker levels 
 
All CSF biomarkers analysed in the study (t-tau, p-tau181, p-tau199) are illustrated in detail 
in the box plots in Figures 1, 2 and 3, with values expressed as medians with 25th and 75th 
percentile (also listed in Table 1). As shown in Table 1, the median levels of all three 
biomarkers (t-tau, p-tau181, and p-tau199) were significantly higher in AD group versus VaD 
and NC groups, whereas comparison of VaD and NC revealed that only t-tau reached 
statistical significance. 
 
Sensitivity and specificity of the CSF markers 
 
Sensitivity and specificity levels, cut-off values, AUC and p values for paired comparisons 
(AD versus VaD and AD versus NC) of a single marker are shown in Table 3. Specificity 
levels for all three analyzed biomarkers, when sensitivity was set at 85% or higher, are shown 
in Figure 4. Additionally, ROC curves of all biomarkers are shown in Figure 4 (paired 
comparison between AD versus VaD) and Figure 5 (paired comparison between AD versus 
NC). ROC analysis in our study revealed that CSF t-tau differentiates between AD and VaD 
with sensitivity and specificity of 100% when the cut-off level was set at 350 pg/mL. P-
tau181 differentiates between the same groups with a sensitivity of 77.8% and a specificity of 
91.7% when the cut-off level was set at 64.5 pg/mL, whereas p-tau199 has a sensitivity of 
88.9% and a specificity of 75% when the cut-off level was set at 52.5 pg/mL. When 
comparing AD and NC groups, t-tau shows a sensitivity of 100% and a specificity of 91.7% 
with a cut-off level set at 390 pg/mL; p-tau181 has a sensitivity of 83.3% and a specificity of 
100% with a cut-off level of 62 pg/mL; and p-tau199 has a sensitivity of 83.3% and a 
specificity of 66.7% with a cut-off level of 55.5pg/mL. P-values for all these comparisons and 
different tau markers were statistically significant (p<0.05). 
Discussion 
 
In the present study, we analyzed the diagnostic accuracy of three different CSF markers (t-
tau, p-tau181, and p-tau199) in differentiation of patients with AD versus VaD and NC. We 
did not find any significant correlation between these biomarkers and MMSE scores. 
Previously, there were variable reports of correlation between MMSE score and various 
biomarkers in CSF, from strong9,10 to insignificant correlations11,12. Although made on a 
limited sample of subjects, our results nevertheless showed significantly higher levels of all 
three markers analyzed in patients with AD compared to those with VaD and NC. Median 
levels of all three CSF markers in our study were comparable to those from previous studies. 
We also analyzed the discriminative power of each marker. For accurate interpretation of the 
results, we used recommendations of a consensus report for useful (ideal) biomarkers of AD, 
and therefore determined specificity levels after the sensitivity levels were set at 85% or 
higher13. According to the consensus report, ideal markers in these conditions should yield a 
specificity of at least 75% to 85%. In our study only t-tau satisfied these recommendations for 
both differentiating AD versus VaD (with specificity of 100%) and AD versus NC (with 
specificity of 91.7%). Additionally, p-tau199 satisfied these criteria for differentiating AD and 
VaD with specificity of 75% (as shown in Table 4). So far, only one study showed high 
discriminatory power in distinguishing between AD and VaD when using the ratio of CSF 
amyloid b42 (the main component of amyloid plaques) and p-tau18114. A prior study which 
was done using CSF t-tau and amyloid b42 levels, yielded specificity of only 48% when 
comparing these two groups12. Levels of p-tau199 showed to be highly specific in 
differentiating AD patients from non-AD group, although differentiation of AD and VaD was 
not investigated15. A recent neuropathological review on assessment of the cognitive impact 
of AD and vascular burden in the aging brain stressed the relative weakness of 
clinicopathological correlations16. To bridge this gap from clinical criteria to 
neuropathological findings, many hopes are currently being directed towards CSF biomarkers. 
In this context, we report here that levels of t-tau and p-tau199 may represent robust markers 
for differentiating AD from VaD. Levels of p-tau181 did not yield adequate level of 
specificity to satisfy consensus recommendations. Since AD and VaD are the most common 
dementias, these results, although from a small series, provide an insight on how to diagnose 
these disorders in the early phase of their progression, which also facilitates the patients’ 
therapeutic management. However, additional studies in larger series, including mixed cases, 
are needed to further explore the potential of these and other CSF markers in early detection 
and tracking of primary causes of cognitive impairment in the elderly. 
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LEGENDS 
 
Fig. 1. Levels of CSF t-tau proteins in patients with AD, VaD and NC subjects. Data are 
presented as box plots. Boxes represent the 25th, 50th (median) and 75th percentiles. 
 
 
Fig. 2. Levels of CSF p-tau181 protein in patients with AD, VaD and NC subjects. Data are 
presented as box plots. Boxes represent the 25th, 50th (median) and 75th percentiles. 
 
Fig. 3. Levels of CSF p-tau199 protein in patients with AD, VaD and NC subjects. Data are 
presented as box plots. Boxes represent the 25th, 50th (median) and 75th percentiles. 
 
 
Fig. 4. ROC curves for CSF t-tau, p-tau181 and p-tau199 when patients with AD were 
compared to VaD patients. Diagonal line indicates an area of 50%, indicating no difference in 
marker levels between groups. 
 
Fig. 5. ROC curves for CSF t-tau, p-tau181 and p-tau199 when patients with AD were 
compared to NC subjects. Diagonal line indicates an area of 50%, indicating no difference in 
marker levels between groups. 
 
 
TABLES 
 
 
TABLE 1 
 
DEMOGRAPHIC CHARACTERISTICS OF GROUPS STUDIED 
 WITH MMSE SCORES AND CSF T-TAU, P-TAU181 AND P-TAU199 LEVELS 
 
 
Age, 
Mean±SD 
(Range), y 
Gender, 
W vs. M, 
No 
MMSE, 
mean±SD 
(Range) 
t-tau, median 
(25th-75th 
percentile), 
pg/ml 
p-tau181, 
median 
(25th-75th 
percentile), 
pg/ml 
p-tau199, 
median (25th-
75th 
percentile), 
pg/ml 
AD 
(n=12) 
66.6 ± 8.1 
(25.8) 
6 vs. 6 
18.3 ± 5.7 
(17) 
725 (489.5-1125) 
77 (69.3-
110.3) 
58.5 (52.3-68) 
NC 
(n=12) 
60.4 ± 10 
(40.2) 
5 vs. 7 
29.5 ± 0.8 
(2.0)* 
192 (94.5-215)* 
50.5 (37.5-
58.3)* 
50 (46-54.8)# 
VaD 
(n=9) 
72.6 ± 5.9 
(18.5) 
4 vs. 5 
17.35 ± 4.4 
(13.0) 
280 (197-310)* ¶ 43 (25.5-68)* 49 (43.5-51.5)* 
 
AD - Alzheimer’s disease, VaD - vascular dementia, NC – normal controls, MMSE - Mini Mental 
Status Examination, T-tau - total tau, P-tau181 - tau phosphorylated at threonine 181, P-tau199 = tau 
phosphorylated at serine 199, * p<0.001 vs. AD, # p<0.008 vs. AD, ¶ p<0.028 vs. NC 
 
 
 
 
TABLE 2 
 
CORRELATION OF MMSE SCORES TO CSF T-TAU, P-TAU181 AND P-TAU 199 
LEVELS IN ALL GROUPS OF SUBJECTS (AD, VAD AND NC) 
 
 
 
 
 
 
 
 
 
Rs=correlation coefficient, *p<0.05 
Group MMSE Rs (t-tau) Rs (p-tau181) Rs (p-tau199) 
AD (n=12) 18.3 ± 5.7 -0.204 0.018 0.025 
NC (n=12) 29.5 ± 0.8 0.168 -0.565 -0.009 
VaD (n=9) 17.35 ± 4.4 -0.252 -0.360 0.377 
TABLE 3 
 
DISCRIMINATIVE VALUES OF CSF MARKERS BETWEEN GROUPS 
 
 Cut-off (pg/ml) Sensitivity (%) Specificity (%) AUC P-value 
AD vs. VaD      
t-tau 350 100 100 1.0 <0.0001 
p-tau181 64.5 77.8 91.7 0.89 0.003 
p-tau199 52.5 88.9 75 0.91 0.002 
 
AD vs. NC      
t-tau 390 100 91.7 0.99 <0.0001 
p-tau181 62 83.3 91.7 0.89 0.001 
p-tau199 55.5 83.3 66.7 0.92 0.009 
 
AUC = area under curve 
 
 
 
TABLE 4 
 
DISCRIMINATIVE POWER BETWEEN GROUPS 
WHEN SENSITIVITY WAS SET ON 85% OR HIGHER 
 
 Specificity (%) 
AD vs. VaD  
t-tau 100 
p-tau181 58.3 
p-tau199 75 
AD vs. NC  
t-tau 91.7 
p-tau181 41.7 
p-tau199 50 
 
 
MARKERI IZ CEREBROSPINALNE TEKUĆINE U DIFERENCIJALNOJ 
DIJAGNOZI ALZHEIMEROVE BOLESTI I VASKULARNE DEMENCIJE 
 
S A Ž E TA K 
 
Alzheimerova bolest (AD) i vaskularna demencija (VaD) dva su najčešća uzroka demencije u 
starih ljudi. Uslijed nedostatka osjetljivosti i specifičnosti kliničkih dijagnostičkih kriterija ova 
se dva poremećaja još uvijek teško razlikuju u praksi. Novija saznanja iz područja 
molekularne i stanične biologije ukazuju da bi korištenje markera iz cerebrospinalne 
tekućine (CSF) moglo unaprijediti ranu detekciju i diferencijalnu dijagnozu AD. Naš je cilj u 
ovom istraživanju bio odrediti dijagnostičku preciznost triju markera iz CSF: ukupnog tau 
proteina (t-tau), tau proteina fosforiliranog na treoninu 181 (p-tau 181) i tau proteina 
fosforiliranog na serinu 199 (p-tau199). Upotrebom komercijalno dostupnih ELISA kitova, 
analizirali smo razine t-tau, p-tau181 i p-tau199 u 12 pacijenata s dijagnozom vjerojatne AD, 
9 pacijenata s VaD i 12 normalnih kontrola (NC). Medijane vrijednosti razina svih triju 
markera bile su značajno više u skupini pacijenata s vjerojatnom AD u odnosu na VaD i NC. 
Ipak, kada je prilikom diferenciranja AD od VaD razina osjetljivosti postavljena na 85% ili 
više, samo su t-tau i p-tau199 zadovoljili međunarodno usuglašene preporučene vrijednosti 
(specifičnost veću od 75%). Zaključno, naši preliminarni podaci na manjoj grupi odabranih 
ispitanika ukazuju da su t-tau i p-tau199 iz CSF korisni markeri za rano diferenciranje AD od 
VaD. 
